NCT05580445View on ClinicalTrials.gov

Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

August 11, 2022

Primary Completion Date

August 11, 2024

Study Completion Date

August 11, 2024

Conditions
Advanced Pancreatic Cancer
Interventions
DRUG

CT-707

Focal Adhesion Kinase (FAK) inhibitor

DRUG

Toripalimab

Programmed Death 1(PD-1) antibody

DRUG

Gemcitabine

nucleoside inhibitor

Trial Locations (1)

200120

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Shouyao Holdings (Beijing) Co. LTD

OTHER